A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 411 participants.

Also called NCT04964557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 411 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04964557
  • EudraCT 2020-005845-18
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Czechia, Denmark, Hungary, Netherlands, Poland, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04964557. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-07 (actual); primary completion 2022-07-15 (actual). Results posted on 2023-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
Acronym
SOLANO
Condition
Hyperlipidaemia
Intervention (Drug)
AZD8233
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04964557
Content hash
d30615132a4fb9c23929a0dcb5a269a942e28e8a82b22b0d5a5a20e94e6906ff